Tags: u.s. stock futures

Futures Creep Up Ahead of More Data, Powell Testimony

Futures Creep Up Ahead of More Data, Powell Testimony
(AP)

Thursday, 07 March 2024 07:53 AM EST

Wall Street futures edged higher Thursday ahead of more economic data and commentary from Jerome Powell after the Federal Reserve chair stuck to the script overnight by saying the central bank still expects to cut rates later this year.

Powell said rate reductions will "likely be appropriate" later this year, "if the economy evolves broadly as expected" and once officials gain more confidence in inflation's steady decline.

The comments kept alive investors' expectations of an interest rate cut in June, giving a boost to U.S equities, which had faltered in the days leading up to the testimony.

Wall Street's main indexes closed higher on Wednesday, with rate-sensitive technology and chip stocks in the lead.

"The much awaited Powell testimony did not provide many surprises. We still expect a 25bp (basis point) cut starting in June and 75-100bp of cuts this year," Mohit Kumar, Jefferies' chief economist for Europe, said in a note.

All eyes will be back on Powell who is set to wrap up his two-day testimony on Thursday.

Investors also awaited jobless claims data due at 8:30 a.m. ET (1330 GMT), which, along with the crucial nonfarm payrolls report on Friday, could provide further details on the strength of the U.S. labor market.

A resilient labor market could make it difficult for the Fed to start cutting interest rates in June, given risks of a pick-up in inflationary pressures.

At 6:55 a.m. ET, Dow e-minis were up 33 points, or 0.09%, S&P 500 e-minis were up 10.25 points, or 0.2%, and Nasdaq 100 e-minis were up 66.75 points, or 0.37%.

Electric carmaker Tesla lagged megacap growth and technology peers in premarket trading, down 1.6%.

Chip stocks such as Nvidia and Micron Technology gained 1.9% and 3.3%, respectively, and were set to extend their rally from the previous session.

Lingerie maker Victoria's Secret & Co dropped 30.7% on a weak annual forecast.

Eli Lilly shed 1.6% after rival Novo Nordisk said early trial data for its highly anticipated experimental drug, amycretin, showed that participants had a weight loss of 13.1% after 12 weeks.

© 2026 Thomson/Reuters. All rights reserved.


StreetTalk
Wall Street futures edged higher Thursday ahead of more economic data and commentary from Jerome Powell after the Federal Reserve chair stuck to the script overnight by saying the central bank still expects to cut rates later this year.
u.s. stock futures
344
2024-53-07
Thursday, 07 March 2024 07:53 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Get Newsmax Text Alerts
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved